Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solidarity Trial for COVID-19 Treatments
NCT04647669Phase 3Unknown
- Sponsor
- The University of the West Indies
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of remdesivir, acalabrutinib and interferon beta-1a in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by The University of the West Indies. Primary endpoint: All cause Mortality at 28 days. Status: unknown.
02
Drugs
remdesiviracalabrutinibinterferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04647669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647669.